Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors
- Conditions
- Refractory or Recurrent Solid TumorsNon-Rhabdomyosarcoma Soft Tissue SarcomaRhabdomyosarcomaEwing Sarcoma
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03245450
- Locations
- 🇩🇪
Eisai Trial Site 6, Essen, Germany
🇩🇪Eisai Trial Site 1, Aachen, Nordrhein-Westfalen, Germany
🇮🇹Ospedale Infantile Regina Margherita, Torino, Piemonte, Italy
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
- Conditions
- Recurrent and Refractory Solid Tumors
- Interventions
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 64
- Registration Number
- NCT03245151
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇺🇸Southern California Permanente Medical Group, Los Angeles, California, United States
Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 2000
- Registration Number
- NCT03208660
- Locations
- 🇺🇸
Meridian Clinical Research, Savannah, Georgia, United States
🇺🇸Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸Northeast Regional Epilepsy Group, Hackensack, New Jersey, United States
Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 343
- Registration Number
- NCT03173560
- Locations
- 🇦🇺
Northern Cancer Institute, Saint Leonards, Saint Leonards, New South Wales, Australia
🇨🇿Nemocnice Na Bulovce, Prague, Czechia
🇺🇸Optimal Research, Honolulu, Hawaii, United States
A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
- Conditions
- Insomnia Disorders
- Interventions
- First Posted Date
- 2017-05-17
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03158025
- Locations
- 🇨🇦
INC Research Toronto, Inc., Toronto, Canada
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects
- Conditions
- Healthy Participants
- Interventions
- Drug: E6742Drug: Placebo
- First Posted Date
- 2017-03-17
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT03082235
- Locations
- 🇺🇸
Parexel International, Glendale, California, United States
Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730
- Conditions
- Healthy Participants
- Interventions
- Drug: E2730Drug: Placebo
- First Posted Date
- 2017-02-15
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03054194
- Locations
- 🇺🇸
Eisai Trial Site, San Antonio, Texas, United States
Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2019-08-01
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT03008447
- Locations
- 🇺🇸
Clinilabs, Inc, New York, New York, United States
🇺🇸NeuroTrials Research, Inc, Atlanta, Georgia, United States
🇺🇸Wake Research Assoicates, LLC, Raleigh, North Carolina, United States
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
- Conditions
- Irregular Sleep-Wake Rhythm Disorder
- Interventions
- Drug: Lemborexant 2.5 mgDrug: Lemborexant 10 mgDrug: Lemborexant 5 mgDrug: Lemborexant 15 mgDrug: Lemborexant-matched placebo
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2021-05-17
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03001557
- Locations
- 🇺🇸
Facility #1, Columbia, South Carolina, United States
🇺🇸Nevada Senior Services (NSS) Adult Day Care Center, Henderson, Nevada, United States
🇯🇵Eisai Trial Site #1, Tachikawa-shi, Tokyo, Japan
Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding
- Conditions
- Hepatic Impairment; Renal Impairment
- Interventions
- Drug: Plasma Sampling
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT02998775
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Inc., Orlando, Florida, United States
🇺🇸DaVita Clinical Research, Minneapolis, Minnesota, United States